» Articles » PMID: 35609674

Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2022 May 24
PMID 35609674
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A shortage of beds in ICUs and conventional wards during the COVID-19 pandemic led to a collapse of health care resources.

Research Question: Can admission data and minor criteria by the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) help identify patients with low-risk SARS-CoV-2 pneumonia?

Study Design And Methods: This multicenter cohort study included 1,274 patients in a derivation cohort and 830 (first wave) and 754 (second wave) patients in two validation cohorts. A multinomial regression analysis was performed on the derivation cohort to compare the following patients: those admitted to the ward (assessed as low risk); those admitted to the ICU directly; those transferred to the ICU after general ward admission; and those who died. A regression analysis identified independent factors for low-risk pneumonia. The model was subsequently validated.

Results: In the derivation cohort, similarities existed among those either directly admitted or transferred to the ICU and those who died. These patients could, therefore, be merged into one group. Five independently associated factors were identified as being predictors of low risk (not dying and/or requiring ICU admission) (ORs, with 95% CIs): peripheral blood oxygen saturation/Fio > 450 (0.233; 0.149-0.364); < 3 IDSA/ATS minor criteria (0.231; 0.146-0.365); lymphocyte count > 723 cells/mL (0.539; 0.360-0.806); urea level < 40 mg/dL (0.651; 0.426-0.996); and C-reactive protein level < 60 mg/L (0.454; 0.285-0.724). The areas under the curve were 0.802 (0.769-0.835) in the derivation cohort, and 0.779 (0.742-0.816) and 0.801 (0.757-0.845) for the validation cohorts (first and second waves, respectively).

Interpretation: Initial biochemical findings and the application of < 3 IDSA/ATS minor criteria make early identification of low-risk SARS-CoV-2 pneumonia (approximately 80% of hospitalized patients) feasible. This scenario could facilitate and streamline health care resource allocation for patients with COVID-19.

Citing Articles

Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia.

Menendez R, Mendez R, Gonzalez-Jimenez P, Latorre A, Reyes S, Zalacain R Sci Rep. 2024; 14(1):12726.

PMID: 38830925 PMC: 11148180. DOI: 10.1038/s41598-024-62718-4.


K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact.

Garcia-Vidal C, Teijon-Lumbreras C, Aiello T, Chumbita M, Menendez R, Mateu-Subira A Infect Dis Ther. 2024; 13(4):715-726.

PMID: 38489118 PMC: 11058153. DOI: 10.1007/s40121-024-00938-x.


Prediction of oxygen supplementation by a deep-learning model integrating clinical parameters and chest CT images in COVID-19.

Kawata N, Iwao Y, Matsuura Y, Suzuki M, Ema R, Sekiguchi Y Jpn J Radiol. 2023; 41(12):1359-1372.

PMID: 37440160 PMC: 10687147. DOI: 10.1007/s11604-023-01466-3.


Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19.

Zysman M, Asselineau J, Saut O, Frison E, Oranger M, Maurac A Eur Radiol. 2023; 33(12):9262-9274.

PMID: 37405504 PMC: 10667132. DOI: 10.1007/s00330-023-09759-x.


Validation of the qSOFA and CRB-65 in SARS-CoV-2-infected community-acquired pneumonia.

Richter T, Tesch F, Schmitt J, Koschel D, Kolditz M ERJ Open Res. 2023; 9(3).

PMID: 37337510 PMC: 10105511. DOI: 10.1183/23120541.00168-2023.